spec sheet6 rows
AC-260584 is an Abbott Laboratories research compound from the 2000s, part of the same M1-muscarinic-agonist wave as sabcomeline and xanomeline but never carried past the tool-compound stage. It was designed as an orally bioavailable, functionally selective M1 agonist that improved cognitive performance in animal testing while sidestepping the receptor subtypes responsible for the GI and cardiac side effects that plagued earlier muscarinic drugs. Unlike some of its contemporaries, AC-260584 does not appear to have been pushed into human trials; its public record is essentially one core pharmacology paper, making it a compound that lives almost entirely in the preclinical literature.
- improved cognitive performance in animal models of memory
- orally bioavailable, unlike many muscarinic agonist candidates of its era
- allosteric mechanism intended to reduce off-target M2/M3 side effects
- theoretical cholinergic side effects shared by the M1-agonist class
- AC-260584 never made it past being a published lab tool compound; Abbott's own pharmacology paper on it functions as basically its entire public research history.
Mechanism
AC-260584 is an orally bioavailable M1 receptor , selectively activating M1 signaling implicated in learning and memory circuits.
Safetyrisks and cautions, not medical advice
Nothing is known about how AC-260584 behaves in a person, because it has never been given to one; its public record is a single Abbott pharmacology paper and no registered trial. The relevant warning comes from its neighbors. Muscarinic agonists reliably produce sweating, salivation, nausea, vomiting, diarrhea and a slowed heart rate once they reach receptors outside the brain, and that peripheral burden is what held back xanomeline for years. Selectivity for M1 was meant to avoid it, but this compound never reached the stage where anyone could check.
History
Developed by Abbott Laboratories in the 2000s as part of a broader M1-agonist research program; characterized in preclinical cognition models but not documented as advancing into human clinical trials.
Resources
This entry is here for reference.
Research
1 listed here; entry last updated July 2026
Reviews
My notesprivate to this device
FAQ
Was AC-260584 ever tested in humans?
There is no well-documented human clinical trial for AC-260584; its public research record is preclinical, centered on a single core pharmacology paper from Abbott.
How is AC-260584 different from other M1 agonists like sabcomeline?
It uses an allosteric aminopyridazine-type mechanism rather than sabcomeline's azabicyclic scaffold, but both share the same underlying goal of selectively activating M1 receptors for cognition while avoiding peripheral muscarinic side effects.
Limitations of the evidence
- no human trial or safety data on public record
Adverse effects
- theoretical cholinergic side effects shared by the M1-agonist class